| BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension |
2021-01-07 |
| BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures |
2021-01-07 |
| BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al |
2021-01-07 |
| Faron Pharmaceuticals–Precision Medicine Group: public relations, 202101 service existent IR by Stern IR |
2021-01-04 |
| Immunicum–Van Herk: investment, 202012c largest shareholder holding 43% after merger of Immunicum with DCprime |
2020-12-31 |
| Hemab–Genmab: antibody technology, 202012 existent license to DuoBody platform to develop antibodies for bleeding disorders |
2020-12-14 |
| Hemab–Novo Group: antibody technology, 202012 existent license to IP to develop antibodies for bleeding disorders from Novo Nordisk AS |
2020-12-14 |
| Hemab–Novo Group: investment, 202012 seed investor Novo Seeds |
2020-12-14 |
| BioInnovation Institute–Novo Group: grant, 202012–203012 up to €470m funding over ten years to BBI from Novo Nordisk Foundation |
2020-12-08 |
| Single Technologies–SEVERAL: investment, 202012 financing round €5m oversubscribed share issue with existing + new investors |
2020-12-04 |
| Enduro Genetics–BioInnovation Institute: credit, 202012 pre-seed loan €470k from BII |
2020-12-02 |
| Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED |
2020-12-01 |
| SynOx Therapeutics–Odlander Fredrikson: investment, 202011 financing round Series A totalling €37m incl co-lead investor HealthCap |
2020-11-19 |
| SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv |
2020-11-19 |
| BioInvent–Van Herk: investment, 202011 existent Van Herk is largest shareholder of BioInvent |
2020-11-18 |
| DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED |
2020-11-18 |
| Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV |
2020-11-12 |
| Emisphere–Novo Group: investment, 202011– acquisition of Emisphere by Novo Nordisk for $1.35b in cash on a cash/debt-free basis |
2020-11-06 |
| The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings |
2020-11-03 |
| Monocl–Definitive Healthcare: investment, 202010 acquisition of Monocl by Definitive Healthcare LLC |
2020-10-29 |
| Galecto–LifeSci: public relations, 202010 supply service existent media contact LifeSci Advisors |
2020-10-28 |
| Galecto–SEVERAL: investment, 202010 US IPO $85m+12.75m with 5.67m+850k common stock shares at $15/share |
2020-10-28 |
| Kaffe Bueno–Denmark (govt): investment, 202010 seed financing round totalling €1.1m incl investor Vaekstfonden |
2020-10-27 |
| Kaffe Bueno–OTHER: investment, 202010 seed financing round totalling €1.1m incl a Danish business angel as investor |
2020-10-27 |
| Kaffe Bueno–Paulig Group: investment, 202010 seed financing round totalling €1.1m incl investor PINC |
2020-10-27 |
| Kaffe Bueno–SEVERAL: investment, 202010 seed financing round €1.1m from PINC + Vaekstfonden + The Yield Lab + a Danish business angel |
2020-10-27 |
| Kaffe Bueno–Yield Lab: investment, 202010 seed financing round totalling €1.1m incl investor The Yield Lab IE |
2020-10-27 |
| Prokarium–Flerie Invest: investment, 202010 financing round Series B totalling $21m incl co-investor Flerie Invest (FF) |
2020-10-27 |
| Prokarium–SEVERAL: investment, 202010 financing round Series B $21m led by Korea Investment Partners |
2020-10-27 |
| Oncopeptides–EU (govt): credit, 202010– unsecured €40m loan facility in three tranches with each 5y maturity from EIB |
2020-10-14 |
| Rappta Therapeutics–Advent Venture Partners: investment, 202010 financing round Series A totalling €9m incl co-investor Advent Life Sciences |
2020-10-13 |
| Rappta Therapeutics–Novartis: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novartis Venture Fund |
2020-10-13 |
| Rappta Therapeutics–Novo Group: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novo Seeds |
2020-10-13 |
| Rappta Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum |
2020-10-13 |
| Rappta Therapeutics–OTHER: investment, 202010 financing round Series A totalling €9m incl a family office as co-investor |
2020-10-13 |
| Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds |
2020-10-13 |
| Priothera–Odlander Fredrikson: investment, 202010 financing round Series A totalling €30m incl co-lead investor HealthCap |
2020-10-12 |
| Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners |
2020-10-12 |
| Rare Thyroid Therapeutics–PledPharma: investment, 202010–202011 acquisition of RTT for SEK60m + 63.77m new shares + milestones |
2020-10-05 |
| Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures |
2020-09-25 |
| Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED |
2020-09-22 |
| Sundew–Novo Group: investment, 202009 seed financing round totalling €1.4m inkl DKK10m (€1.34m) from Novo Nordisk BII |
2020-09-22 |
| Sundew–SEVERAL: investment, 202009 seed financing round €1.4m with €1.34m from Novo Nordisk BII + €85k from StartLife |
2020-09-22 |
| Sundew–StartLife (NL): investment, 202009 seed financing round totalling €1.4m inkl €85k from StartLife |
2020-09-22 |
| Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures |
2020-09-17 |
| Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures |
2020-09-17 |
| Umotif–SEVERAL: investment, 202009 financing round Series A £5m led by existing investor AlbionVC |
2020-09-03 |
| Cartana–10x Genomics: investment, 202008 acquisition of Cartana AB by 10x Genomics Inc |
2020-08-31 |
| Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares |
2020-08-19 |
| Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED |
2020-08-13 |
| F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures |
2020-08-12 |
| F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors |
2020-08-12 |
| Oasmia–Consilium: public relations, 202008 service existent by CSC |
2020-08-10 |
| Reapplix–Denmark (govt): investment, 202007 financing round totalling DKK150m ($22.6m) incl existing investor Vaekstfonden |
2020-07-14 |
| Reapplix–Lauxera Capital: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Lauxera Capital Partners |
2020-07-14 |
| Reapplix–MK Ventures: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor MK Ventures |
2020-07-14 |
| Reapplix–North East Health Care: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor North East Health Care |
2020-07-14 |
| Reapplix–Novo Group: investment, 202007 financing round totalling DKK150m ($22.6m) incl existing investor Novo Holdings |
2020-07-14 |
| Reapplix–PERSON: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Bo Jesper Hansen |
2020-07-14 |
| Reapplix–PERSON: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Jan Struve |
2020-07-14 |
| Reapplix–SEVERAL: investment, 202007 financing round DKK150m ($22.6m) from new + existing investors |
2020-07-14 |
| Eir Ventures–Denmark (govt): investment, 202007 first closing totalling €76m incl investor Vaekstfonden |
2020-07-10 |
| Eir Ventures–EU (govt): investment, 202007 first closing totalling €76m incl investor EIF |
2020-07-10 |
| Eir Ventures–Novo Group: investment, 202007 first closing totalling €76m incl investor Novo Holdings |
2020-07-10 |
| Eir Ventures–Optimum Strategic Communications: public relations, 202007 service existent by Optimum |
2020-07-10 |
| Eir Ventures–SEVERAL: investment, 202007 first closing €76m from Saminvest + EIF + Vaekstfonden + Novo Holdings + private investors |
2020-07-10 |
| Eir Ventures–Sweden (govt): investment, 202007 first closing totalling €76m incl investor Saminvest |
2020-07-10 |
| VarmX–SEVERAL: investment, 202007 financing round Series B €32m co-led by Ysios Capital + INKEF Capital |
2020-07-08 |
| Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund |
2020-07-03 |
| Freeline Therapeutics–Novo Group: investment, 202006 financing round Series C final closing totalling $80m incl co-lead investor Novo Holdings A/S |
2020-06-30 |
| Freeline Therapeutics–SEVERAL: investment, 202006 financing round Series C final closing $80m (£61.2m) co-led by Novo Holdings + Eventide + Wellington |
2020-06-30 |
| JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV |
2020-06-12 |
| Corvidia Therapeutics–Goodwin Procter: legal services, 202006 supply service legal advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–JPMorgan Chase: financial services, 202006 supply service advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED |
2020-06-11 |
| Novo Group–Davis Polk & Wardell: legal services, 202006 supply service legal advisor to Novo Nordisk for acquisition of Corvidia Therapeutics |
2020-06-11 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications |
2020-06-08 |
| NodThera–Novo Group: investment, 202006 financing round Series B totalling £44m ($55m) incl lead investor Novo Ventures |
2020-06-03 |
| NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures |
2020-06-03 |
| Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility |
2020-05-27 |
| Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital |
2020-05-26 |
| Kaiku Health–Elekta: investment, 202005 acquisition 100% of Kaiku Health by Elekta |
2020-05-15 |
| Calliditas Therapeutics–SEVERAL: investment, 202005–202006 private placement SEK82.9m with 924k common shares at SEK89.7/share outside US |
2020-05-14 |
| Calliditas Therapeutics–SEVERAL: investment, 202005–202007 US IPO $81m+$6.9m with w 8.3m+707k common shares as ADSs at Nasdaq Global Market |
2020-05-14 |
| Oncopeptides–SEVERAL: investment, 202005 directed share issue SEK1.414b ($144m) with 12.295m new shares at SEK115/share |
2020-05-05 |
| EnginZyme–SEVERAL: investment, 202004 financing round Series A €6.4m led by Sofinnova Partners |
2020-04-22 |
| EnginZyme–Sofinnova: investment, 202004 financing round Series A totalling €6.4m incl lead investor Sofinnova Industrial Biotech Fund |
2020-04-22 |
| Leo Pharma–Oneness Biotech: therapeutic antibody, 202004– license ww excl to FB825 $40m upfront + $530m milestones + royalties from Oneness + MBS |
2020-04-15 |
| Servier–Gorrissen Federspiel: legal services, 202004 supply service Gorrissen Federspiel legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Servier–Lazard: financial services, 202004 supply service Lazard financial advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Servier–McDermott Will & Emery: legal services, 202004 supply service MWE legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Symphogen–Perkins Coie: legal services, 202004 supply service Perkins Coie legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Plesner: legal services, 202004 supply service Plesner AP legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Rothschild & Co: financial services, 202004 supply service Rothschild & Co financial advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Servier: investment, 202004–202006 acquisition 100% €na |
2020-04-03 |
| Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments |
2020-03-31 |
| Obi Medical–Roche: investment, 202003 acquisition of Obi Medical ApS by Roche |
2020-03-31 |
| Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings |
2020-03-13 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
